Advertisement

Advertisement
COVID-19

Impact of COVID-19 on Cancer Treatment and Early Detection: Data-Driven Insights

From a dramatic drop in caseloads to missed screenings and diagnoses as well as the emergence of telemedicine, COVID-19 turned the world of oncology upside down. During the National Comprehensive Cancer Network (NCCN) Virtual Oncology Policy Summit, “Defining the ‘New Normal’ 2021 and the State of Cancer Care in America,” Murray Aitken, MA, MBA, Executive Director of the IQVIA Institute for Human Data Science, shared data-driven insights on the pandemic’s impact on cancer care.

 

Lung Cancer
Immunotherapy

Addition of Ipilimumab to Nivolumab in Previously Treated, Immunotherapy-Naive Patients With Stage IV Squamous NSCLC

As reported in JAMA Oncology by Scott N. Gettinger, MD, and colleagues, the phase III Lung Cancer Master Protocol S1400I trial showed no improvement in overall survival with the addition of ipilimumab to nivolumab in previously treated, immune checkpoint inhibitor–naive patients with stage IV squamous non–small cell lung cancer (NSCLC).

 

Breast Cancer

Outcomes in Patients With HER2-Low–Positive Breast Cancer Participating in Neoadjuvant Clinical Trials

In a pooled analysis of individual patient data from breast cancer neoadjuvant clinical trials reported in The Lancet Oncology, Carsten Denkert, MD, and colleagues found that pathologic complete response and survival rates for patients with HER2-low–positive vs HER2-zero tumors differed according to hormone receptor (HR) status.

 


Advertisement
Prostate Cancer

Nomograms for Predicting Outcomes With LuPSMA Therapy in Metastatic Castration-Resistant Prostate Cancer

In a retrospective study reported in The Lancet Oncology, Gafita et al developed nomograms for predicting overall survival and prostate-specific antigen (PSA) progression-free survival outcomes in men receiving lutetium-177–PSMA (LuPSMA) treatment for metastatic castration-resistant prostate cancer.

 

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement



Sponsored Content


Lung Cancer
Immunotherapy

Martin Reck, MD, PhD, on NSCLC: Nivolumab, Ipilimumab, and Chemotherapy for Advanced Disease

Issues in Oncology

Community-Based Engagement Initiative Improves Accrual of Black Participants in Clinical Trials

A 5-year community outreach and engagement effort by the Abramson Cancer Center at the University of Pennsylvania to increase enrollment of Black patients into cancer clinical trials more than doubled the percentage of participants, improving access and treatment for a group of patients with...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Breast Cancer

Priya Rastogi, MD, on Breast Cancer: Predicting the Benefit of Extended Letrozole Therapy

Gynecologic Cancers

HIPEC With Carboplatin for Platinum-Sensitive Recurrent Ovarian Cancer: Safety and Outcomes

In an MSK Team Ovary–led phase II trial reported in the Journal of Clinical Oncology, Zivanovic et al found that use of hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin during secondary cytoreduction followed by chemotherapy did not improve 24-month progression-free survival in...

Prostate Cancer

Novel PSMA-Targeted Radiotherapy Improves Radiographic Progression-Free and Overall Survival in Metastatic Prostate Cancer

Lutetium-177–PSMA-617 (Lu-177–PSMA-617)—an investigational radioligand therapy—significantly improved radiographic progression-free survival and overall survival when added to standard of care compared with standard of care alone for men with metastatic castration-resistant prostate cancer whose...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Prostate Cancer

Neeraj Agarwal, MD, on Prostate Cancer: Androgen-Deprivation Therapy With Orteronel or Bicalutamide

FDA Approves New Pediatric Indication for Technetium Tc 99m Tilmanocept Injection

The Lymphoseek (technetium Tc 99m tilmanocept) injection—a radiopharmaceutical agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsies—has been approved for pediatric use by the U.S. Food and Drug Administration (FDA). "This new indication opens the door ...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...